SESSION TITLE: COPD III
SESSION TYPE: Slide Presentation
PRESENTED ON: Monday, March 24, 2014 at 10:45 AM - 11:45 AM
PURPOSE: Recently, the CAT is recommended as a promising tool for assessing the impact of COPD on the indivudual patient. Although it was known that COPD patients have a high frequency of comorbidities, little known about the contribution of these comorbidities to CAT score. We aimed to assess the impact of comorbidities on disease specific health status as assessed by CAT in patients with stable COPD.
METHODS: This is a cross-sectional study of 142 COPD patients who completed the CAT. Data were recorded in stable state and included spirometry, dyspnea (modified Medical Research Council - mMRC-scale), body mass index (BMI), exacerbation frequency and hospitalisation rate in the previous year, and physician-diagnosed comorbidities including diabetes, hypertension, coronary artery disease, chronic heart failure, depression). Stepwise forward and backward multiple regression analyses were performed to examine the contribution of comorbidities to CAT scores.
RESULTS: Patients had a mean age of 60.9±8.7, FEV1 of 54.8±18.4% predicted, CAT score of 14.16±7.4 units. 97 (68.3%) of patients had at least one comorbidity. Cardiovascular diseases (60.8%), metabolic diseases (40.2%), and anxiety/depression (21.6%) were the most prevalent ones. CAT scores in patients with a comorbidity were significantly higher than without comorbidity (p<0.05). In univariate analysis, positive correlations were found between CAT scores and age and dyspnea, whereas negative correlations were found with FEV1 in COPD patients with comorbidities (p < 0.001 for each variable), but not in subjects without comorbidities. In multivariate analyses, major independent determinants of CAT score included older age, dyspnea and presence of any comorbidity.
CONCLUSIONS: These data suggest that older age and the presence of dyspnea and comorbidity are the important contributors to CAT score in COPD subjects, whereas FEV1 have only limited impact.
CLINICAL IMPLICATIONS: Detailed evaluation and treatment of these associated comorbidities may improve the prognosis of this patients.
DISCLOSURE: The following authors have nothing to disclose: Sibel Atis Nayci, Eylem Sercan Özgür, Cengiz Özge, Yasin Duman, Ahmet Ilvan
No Product/Research Disclosure Information